| Title | Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer |
| Authors | Yao, Lu Zhang, Juan Liu, Yiqiang Ouyang, Tao Li, Jinfeng Wang, Tianfeng Fan, Zhaoqing Fan, Tie Lin, Benyao Xie, Yuntao |
| Affiliation | Peking Univ, Canc Hosp, Beijing Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China. Peking Univ, Canc Hosp, Beijing Canc Hosp & Inst, Breast Ctr, Beijing 100142, Peoples R China. Peking Univ, Canc Hosp, Beijing Canc Hosp & Inst, Dept Pathol, Beijing 100142, Peoples R China. |
| Keywords | HER2 breast cancer neoadjuvant chemotherapy paclitaxel carboplatin PATHOLOGICAL COMPLETE RESPONSE SURGICAL ADJUVANT BREAST LONG-TERM SURVIVAL PREOPERATIVE CHEMOTHERAPY SYSTEMIC THERAPY CYCLOPHOSPHAMIDE DOXORUBICIN CHINA TRIAL FLUOROURACIL |
| Issue Date | 2015 |
| Publisher | CHINESE JOURNAL OF CANCER RESEARCH |
| Citation | CHINESE JOURNAL OF CANCER RESEARCH.2015,27,(6),553-561. |
| Abstract | Background: We recently showed HER2-positive breast cancers are less likely to respond to neoadjuvant anthracycline chemotherapy. Here, we investigated whether HER2-positive breast cancers responded to sequential neoadjuvant anthracycline followed by paclitaxel plus carboplatin regimen in the absence of trastuzumab. Methods: Women (n=372) with operable primary breast cancer initially received two cycles of neoadjuvant anthracyclines, the clinical tumor response was assessed, then patients were received four cycles of paclitaxel plus carboplatin regimen. All the patients did not received trastuzumab treatment in the neoadjuvant setting. HER2 status was determined by immunohistochemistry and/or by fluorescence in situ hybridization in core-biopsy breast cancer tissue obtained before the neoadjuvant chemotherapy. Results: Eighteen percent (67/372) of patients achieved a pathologic complete response (pCR) in their breast. HER2-positive tumors had a significant higher pCR rate than HER2-negative tumors (33.0% versus 13.5%, P<0.001) in this cohort of 372 patients, and positive HER2 status remained an independent favorable predictor of pCR in a multivariate analysis [odds ratio (OR), 2.26; 95% confidence interval (CI), 1.18 to 4.36, P=0.015]. Furthermore, patients who responded to initial anthracycline regimens were more likely to respond to paclitaxel plus carboplatin than patients who did not (pCR, 27.2% versus 14.6%, P=0.005). Patients with HER2-positive tumors exhibited a significant higher pCR rate than did patients with HER2-negative tumors in both anthracycline response group (40.5% versus 20.0%, P=0.025) and anthracycline non-response group (28.3% versus 11.3%, P=0.002). Conclusions: Under the circumstance of no trastuzumab treatment, women with HER2-positive cancers derive a large benefit from paclitaxel-carboplatin-based neoadjuvant chemotherapy. |
| URI | http://hdl.handle.net/20.500.11897/435433 |
| ISSN | 1000-9604 |
| DOI | 10.3978/j.issn.1000-9604.2015.12.03 |
| Indexed | SCI(E) PubMed 中国科技核心期刊(ISTIC) 中国科学引文数据库(CSCD) |
| Appears in Collections: | 北京肿瘤医院 |
